GPT and metabolic dysfunction-associated steatotic liver disease: In a systemic review and meta-analysis of 8 randomized controlled clinical trials involving 468 patients which evaluated the efficacy of GLP-1RAs in patients with T2DM and NAFLD, GLP-1RAs significantly decreased liver fat content measured using MRI, along with alanine aminotransferase (weighted mean difference [WMD] = −3.82 IU/L; 95% CI, −7.04 to −0.60; P = .02), aspartate aminotransferase (WMD = −2.4 IU/L; 95% CI, −4.55 to −0.25; P = .03), HbA1c, total cholesterol, and triglycerides, whereas no improvement was shown in FIB-4 index [37].